Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMC 3140175)

Published in Clin Infect Dis on April 15, 2008

Authors

Perumal Vivekanandan1, Rajesh Kannangai, Stuart C Ray, David L Thomas, Michael Torbenson

Author Affiliations

1: Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA.

Articles citing this

Occult HBV infection. Semin Immunopathol (2012) 1.37

Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev (2012) 1.30

Methylation regulates hepatitis B viral protein expression. J Infect Dis (2009) 1.07

Occult hepatitis B: clinical implications and treatment decisions. Dig Dis Sci (2010) 1.06

Hepatitis B virus replication induces methylation of both host and viral DNA. J Virol (2010) 1.03

Regulation of hepatitis B virus replication by epigenetic mechanisms and microRNAs. Front Genet (2013) 0.99

Therapeutics Based on microRNA: A New Approach for Liver Cancer. Curr Genomics (2010) 0.96

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Med Microbiol Immunol (2010) 0.88

Comparative analysis of CpG islands among HBV genotypes. PLoS One (2013) 0.87

Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol (2016) 0.82

Occult Hepatitis B Virus Infection in a Previously Vaccinated Injection Drug User. Hepat Mon (2016) 0.81

Characterization of Novel Hepatitis B Virus PreS/S-Gene Mutations in a Patient with Occult Hepatitis B Virus Infection. PLoS One (2016) 0.78

The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection. Front Microbiol (2016) 0.77

Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis (2015) 0.77

Mutations associated with occult hepatitis B in HIV-positive South Africans. J Med Virol (2014) 0.76

Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One (2014) 0.76

Update on occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75

Genetic variation of occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75

Occult hepatitis B virus infection in liver transplant patients in a Brazilian referral center. Braz J Med Biol Res (2014) 0.75

Molecular characterization of occult hepatitis B virus infection in patients with end-stage liver disease in Colombia. PLoS One (2017) 0.75

Articles cited by this

Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15

"Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet (1994) 3.33

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

Occult hepatitis B virus infection. J Hepatol (2006) 2.79

Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci U S A (2005) 2.68

Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology (2005) 2.49

G to A hypermutation of hepatitis B virus. Hepatology (2005) 1.83

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81

Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology (1999) 1.80

Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine (1995) 1.71

Occult HBV infection in cryptogenic liver cirrhosis in an area with high prevalence of HBV infection. Am J Gastroenterol (2002) 1.68

Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut (2005) 1.66

Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61

Occult hepatitis B virus infection in chronic liver disease: full-length genome and analysis of mutant surface promoter. Gastroenterology (2004) 1.40

Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer (2006) 1.33

Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 1.31

High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology (2004) 1.23

Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol (1998) 1.21

A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun (2002) 1.20

Quantitative analysis of hepatitis B virus DNA by real-lime amplification. Eur J Clin Microbiol Infect Dis (2002) 1.18

Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol (2002) 1.16

Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol (2006) 1.16

Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl (2004) 1.14

Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clin Virol (2007) 1.10

Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat (2004) 1.07

Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat (2008) 1.06

Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol (2005) 1.06

Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. J Viral Hepat (2001) 1.02

Molecular epidemiology and immunology of hepatitis B virus infection - an update. Intervirology (2002) 0.99

Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen-negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR. Intervirology (2007) 0.95

Isolation, characterization and biological significance of hepatitis B virus mutants from serum of a patient with immunologically negative HBV infection. J Hepatol (2000) 0.93

Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. J Gen Virol (1999) 0.85

Articles by these authors

Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53

Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94

HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22

Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19

Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13

Protection against persistence of hepatitis C. Lancet (2002) 5.94

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol (2006) 5.41

Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06

Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38

Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30

Hepatitis C and progression of HIV disease. JAMA (2002) 3.15

Occult hepatitis B. Lancet Infect Dis (2002) 3.09

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06

IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02

In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01

Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00

Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99

Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol (2006) 2.91

Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71

Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67

Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64

Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61

G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61

Needlestick transmission of hepatitis C. JAMA (2002) 2.55

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45

Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34

Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24

MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23

High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20

Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med (2005) 2.16

mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res (2004) 2.14

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology (2012) 2.14

Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene (2003) 2.11

Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis (2005) 2.02

Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis (2007) 1.96

Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J Infect Dis (2009) 1.93

Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92

Cross-genotype immunity to hepatitis C virus. J Virol (2004) 1.92

Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis (2005) 1.91

Hepatitis C virus infection and incident type 2 diabetes. Hepatology (2003) 1.89

Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology (2009) 1.89

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol (2002) 1.88

Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88

Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85

HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82

Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82

Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80

High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol (2008) 1.79

The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology (2007) 1.78

Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74

Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol (2010) 1.66

Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol (2008) 1.66

High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. J Assoc Physicians India (2009) 1.66

Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology (2002) 1.65

Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63

Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 1.63

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health (2004) 1.62

Hyperlactataemia syndromes associated with HIV therapy. Lancet Infect Dis (2003) 1.57

Tuberculosis-associated haemophagocytic syndrome. Lancet Infect Dis (2006) 1.55

Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. Hum Pathol (2013) 1.54

Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53

Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52

A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts. J Virol Methods (2006) 1.49

Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg (2007) 1.46

Relation between vitamin D status and nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr (2015) 1.44

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44

Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42

Prospective study of infective endocarditis among injection drug users. J Infect Dis (2002) 1.41

Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41

HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41

Chemokine profile among human immunodeficiency virus-1 (HIV-1) infected individuals from southern India. Indian J Med Res (2008) 1.39

Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology (2006) 1.38

Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36